@article {8059,
	title = {Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer},
	journal = {Annals of Oncology},
	volume = {14},
	year = {2003},
	note = {Cited By :27Export Date: 21 February 2017},
	month = {2003},
	pages = {1094 - 1099},
	abstract = {Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. Patients and methods: Treatment consisted of vinorelbine 25 mg/m2 as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m2, as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. Results: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75\% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5\% of all patients; 7.3\% of evaluable patients) achieved complete response and eight (17.4\% and 19.5\%, respectively) a partial response to chemotherapy leading to overall response rates of 23.9\% and 26.8\%, respectively. Another 34.8\% (39.0\%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31\%), neutropenia (35\%) and febrile neutropenia (20\%). Conclusions: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer.},
	keywords = {Chemotherapy, Docetaxel, Ovarian cancer, Platinum-resistant, Vinorelbine},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0042200675\&doi=10.1093\%2fannonc\%2fmdg292\&partnerID=40\&md5=54057ff4731f7e565c14a038c4d92c59},
	author = {Aravantinos, G. and Bafaloukos, D. and Fountzilas, G. and Christodoulou, C. and Papadimitriou, C. and N. Pavlidis and Kalofonos, H.P. and Gogas, H. and Kosmidis, P. and Dimopoulos, M.A.}
}
